Home Journals Articles Updates About
CN
image
收藏切换
New approved drug for the treatment of relapsed or refractory pediatric low-grade glioma——Tovorafenib
收藏切换
PDF
Ting-ting BIAN1a, Du-han BO1b, Xin HE2, Yan-ni CHEN2
Chinese Journal of Clinical Pharmacology | 2025, 41(2) : 250 - 253
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(2): 250-253
• New Drugs Introduction •
New approved drug for the treatment of relapsed or refractory pediatric low-grade glioma——Tovorafenib
Full
Ting-ting BIAN1a, Du-han BO1b, Xin HE2, Yan-ni CHEN2
Affiliations
  • 1a.Department of Pharmacy, Yangzhou Maternal and Child Health Care Hospital Affiliated to Medical College of Yangzhou University, Yangzhou 225000, Jiangsu Province, China
  • 1b.Department of Pediatrics, Yangzhou Maternal and Child Health Care Hospital Affiliated to Medical College of Yangzhou University, Yangzhou 225000, Jiangsu Province, China
  • 2.Department of Pharmacy, Women’s Hospital of Nanjing Medical University, Nanjing Women and Children’s Healthcare Hospital, Nanjing 210004, Jiangsu Province, China
Published: 2025-01-28 doi: 10.13699/j.cnki.1001-6821.2025.02.020
Outline
收藏切换

Tovorafenib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma(LGGs) harboring the serine threonine kinae v-RAF murine sarcoma viral oncogene homologue B1 (BRAF) fusion or rearrangement, or BRAV600E mutation. Tovorafenib is an oral, greater brain-penetrant, selective, type Ⅱ RAF inhibitor which has potent activity against both oncogenic BRAF fusions and BRAFV600E mutations. Most tumors have been showed some degree of shrinkage. The mechanism of action, pharmacodynamics, pharmacokinetics, clinical study and safety were introduced.

Tovorafenib  /  pediatric low-grade glioma  /  RAF inhibitor  /  the serine threonine kinae v-RAF murine sarcoma viral oncogene homologue B1 gene fusion
Ting-ting BIAN, Du-han BO, Xin HE, Yan-ni CHEN. New approved drug for the treatment of relapsed or refractory pediatric low-grade glioma——Tovorafenib[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (2) : 250 -253 . DOI: 10.13699/j.cnki.1001-6821.2025.02.020
Appendix
Less
Year 2025 volume 41 Issue 2
PDF
2
1
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.02.020
  • Receive Date：2024-06-13
  • Online Date：2026-08-04
  • Published：2025-01-28
Article Data
Affiliations
History
  • Received：2024-06-13
Funding
Affiliations
    1a.Department of Pharmacy, Yangzhou Maternal and Child Health Care Hospital Affiliated to Medical College of Yangzhou University, Yangzhou 225000, Jiangsu Province, China
    1b.Department of Pediatrics, Yangzhou Maternal and Child Health Care Hospital Affiliated to Medical College of Yangzhou University, Yangzhou 225000, Jiangsu Province, China
    2.Department of Pharmacy, Women’s Hospital of Nanjing Medical University, Nanjing Women and Children’s Healthcare Hospital, Nanjing 210004, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.02.020
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House